Prospective, Dose-Escalating, Investigator Initiated Trial to Evaluate the Safety and Efficacy of ZM-01 in 3-18 Year-old Male Subjects With X-linked Retinoschisis
Latest Information Update: 26 Feb 2024
At a glance
- Drugs AAV RS1 (Primary)
- Indications Retinoschisis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Zhongmou Therapeutics
Most Recent Events
- 10 Oct 2023 New trial record